BioSante: Study Generates Confidence For Future Treatment

By Ganaxi Small Cap Movers:Biosante Pharmaceuticals (BPAX) announced after the market closed today that its lead product in development, Libigel, often incorrectly called Viagra for women, had failed based on an initial analysis of data from two pivotal phase 3 efficac

Sheff Station submits:Biosante’s potential breakthrough product, Libigel, is in Phase III clinical trials for the treatment of female sexual dysfunction. Libigel does not have a partner for the product, and currently there is no pharmaceutical product approved in the U.S.

Kaushik Paul submits:By May 2011, an independent Data Monitoring Committee (DMC) is expected to review the Phase III safety trial data of BioSante Pharmaceuticals, Inc.'s (BPAX) Libigel, a drug designed for the treatment of female sexual dysfunction (FSD) in surgically menopausal women.

By James Stocklasar Thomas Jr.:Biosante (BPAX) deserves attention from the Seeking Alpha community, especially since it was at center stage of the penny-land biotech community going into December 2011. The question on Biosante's investors' minds is: Will Libigel make a comeback? I imagine answers range from the pejorative to unbridled optimism, from, 'No way!' to 'Yes way!'

By Kinetic Investments: By Bert Wilkison

ByAli Yasar:The news of failed Phase III efficacy studies on Libigel (testosterone gel) being used as a treatment for female sexual dysfunction (FSD) was a surprise to many Biosante Pharmaceuticals (BPAX) investors.

By Williams Equity Analysis: BioSante Pharmaceuticals (BPAX) is a biotech company based out of Illinois. The stock has risen about 40% since June 20th with the absence of any major news, so there is significant risk of a short-term pullback. Pipeline

By Smith On Stocks: Investment Overview